DE69132291T2 - Xanthinderivate - Google Patents

Xanthinderivate

Info

Publication number
DE69132291T2
DE69132291T2 DE69132291T DE69132291T DE69132291T2 DE 69132291 T2 DE69132291 T2 DE 69132291T2 DE 69132291 T DE69132291 T DE 69132291T DE 69132291 T DE69132291 T DE 69132291T DE 69132291 T2 DE69132291 T2 DE 69132291T2
Authority
DE
Germany
Prior art keywords
substituted
group
unsubstituted
formula
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132291T
Other languages
English (en)
Other versions
DE69132291D1 (en
Inventor
Glynn Smith
Richard Buckle
Edward Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909027899A external-priority patent/GB9027899D0/en
Priority claimed from GB909027752A external-priority patent/GB9027752D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of DE69132291D1 publication Critical patent/DE69132291D1/de
Publication of DE69132291T2 publication Critical patent/DE69132291T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
DE69132291T 1990-12-21 1991-12-19 Xanthinderivate Expired - Fee Related DE69132291T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909027899A GB9027899D0 (en) 1990-12-21 1990-12-21 Novel compounds
GB909027752A GB9027752D0 (en) 1990-12-21 1990-12-21 Novel compounds
PCT/GB1991/002286 WO1992011260A1 (en) 1990-12-21 1991-12-19 Xanthine derivatives

Publications (2)

Publication Number Publication Date
DE69132291D1 DE69132291D1 (en) 2000-08-10
DE69132291T2 true DE69132291T2 (de) 2000-12-14

Family

ID=26298155

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132291T Expired - Fee Related DE69132291T2 (de) 1990-12-21 1991-12-19 Xanthinderivate

Country Status (14)

Country Link
US (1) US5409934A (de)
EP (1) EP0563168B1 (de)
JP (1) JPH06504534A (de)
KR (1) KR930703319A (de)
AT (1) ATE194345T1 (de)
AU (1) AU649091B2 (de)
CA (1) CA2098846A1 (de)
DE (1) DE69132291T2 (de)
ES (1) ES2148170T3 (de)
IE (1) IE914502A1 (de)
MX (1) MX9102766A (de)
NZ (1) NZ241158A (de)
PT (1) PT99919B (de)
WO (1) WO1992011260A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
CA2218548A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
US6133273A (en) * 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
US6221874B1 (en) * 1998-05-08 2001-04-24 American Home Products Corporation Method of treating bone loss by stimulation of calcitonin
EP1208100B1 (de) * 1999-08-31 2003-04-02 Vanderbilt University Selektive antagonisten von a2b adenosinrezeptoren
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP3998118B2 (ja) * 2000-10-10 2007-10-24 本田技研工業株式会社 電動車両
CN1781920A (zh) * 2001-08-28 2006-06-07 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
MXPA04004370A (es) * 2001-11-09 2004-08-11 Schering Corp Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
EP1719772A1 (de) 2002-05-31 2006-11-08 Schering Corporation Verfahren zur Herstellung von Xanthin Phosphodiesterase v Inhibitoren und deren Vorstufen
US6924140B2 (en) * 2002-06-14 2005-08-02 Lewis J. Daly Closed loop work station bioremediation using mini-reactor cartridges
AU2003231805A1 (en) * 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
EP1648895B1 (de) * 2003-07-31 2007-05-30 Schering Corporation Metabolit eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
EP1691788A2 (de) * 2003-11-21 2006-08-23 Schering Corporation Phosphodiesterase-v-inhibitorformulierungen
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
EP2023729B1 (de) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organische verbindungen
CN101969774A (zh) 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900474A (en) * 1973-05-14 1975-08-19 Kendall & Co Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916469A1 (de) * 1989-05-20 1990-11-22 Basf Ag Sulfonamide
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
IE914502A1 (en) 1992-07-01
JPH06504534A (ja) 1994-05-26
AU649091B2 (en) 1994-05-12
ATE194345T1 (de) 2000-07-15
EP0563168A1 (de) 1993-10-06
PT99919B (pt) 1999-06-30
CA2098846A1 (en) 1992-06-22
DE69132291D1 (en) 2000-08-10
PT99919A (pt) 1992-12-31
NZ241158A (en) 1994-12-22
WO1992011260A1 (en) 1992-07-09
KR930703319A (ko) 1993-11-29
EP0563168B1 (de) 2000-07-05
MX9102766A (es) 1992-09-01
ES2148170T3 (es) 2000-10-16
US5409934A (en) 1995-04-25
AU9122791A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
DE69132291T2 (de) Xanthinderivate
MY109737A (en) Treatment and compounds.
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0464846T3 (da) Imidderivater og deres fremstilling og anvendelse
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
ES8306093A1 (es) Procedimiento de preparacion de derivados aminoalcoil heterociclicos farmaceuticamente activos.
ES8102104A1 (es) Un procedimiento para la preparacion de nuevos derivados - hete rociclicos.
EP0365364A3 (de) 2-Azetidinonderivate
DE69003200T2 (de) Arylsubstituierte Aminderivate verwendbar in der Krebstherapie.
DK0501892T3 (da) Diazoterede heterocykliske N-substituerede derivater, der indeholder en biphenylmethylgruppe, fremstilling af derivaterne samt lægemidler indeholdende disse
DE69206274D1 (de) 3-ureido-benzodiazepinone verwendbar als cck- oder gastrin-antagonisten.
MY116952A (en) 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation
SE9603283D0 (sv) New compounds
IL106387A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
SE8101464L (sv) 2-penem-3-karboxylsyraderivat, deras framstellning och anvendning
DK0514442T3 (da) N-Phenyl-N-acetamidoglycinamider, deres fremstilling og lægemidler med indehold deraf
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
DK0677042T3 (da) Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler
KR860000286A (ko) 디히드로피리딘 유도체의 제조방법
ES8401456A1 (es) Procedimiento para la preparacion de 2-aminometilfenoles.
DK356287A (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
HUP9902041A2 (hu) Új kinoxalin-dion-származékok, a vegyületek előállítása és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee